BC Platforms, a world leader in genomic data management solutions today announces that it has signed a partnership with Codigo46, an emerging Mexican company, focused on building and managing the largest biobank in Latin America in co-operation with Mexican health and research specialists to deliver clinical patient benefits and future personalised medicines through academic and commercial research. This biobank, which is unique due to the Mexican genotype which has a native American and European mix, is expected to grow to over one million genotypic and phenotypic data samples over the next three years.
BC Platforms will deliver a bespoke technology platform enabling Codigo46’s global customers and collaborators to efficiently access and analyse this data without compromising its integrity. This platform will provide automated systems and high end infrastructure to enable the acquisition of large volumes of data from new sources. Codigo46 has adopted Illumina’s recently announced Infinium® Global Screening Array (GSA). The chip has been designed for genetic risk screening of large global populations.
Lorenza Haddad, Chief Executive Officer at Codigo46, commented: “We are very excited to partner with BC Platforms. We believe that with their support and expertise we can achieve our ambitious goal to build the largest biobank in Latin America. Our ambitions are not just to generate a genetic database, but also to incorporate clinical data from hospital systems with patient consent and be a part of different research projects. It will be the first biobank to provide such extensive data sets from subjects of this diverse genotype and we expect it will be a highly valuable resource for academic and commercial research across the globe.”
Tero Silvola, Chief Executive Officer at BC Platforms, commented: “We feel privileged to collaborate with Codigo46 on this unique project and support the translation of these diverse samples into valuable data for academic and commercial research. We are excited to work in partnership to develop a bespoke technology platform to support them in their mission to build the largest biobank in Latin America.”
Codigo46 is an emerging Mexican company partnering with world leaders in the genomic field to build the most extensive biobank in Latin America. Codigo46 wants to bridge the gap between the promises of personalized medicine and reality, contributing to research, development, and health programs. Using Illumina’s recently announced Infinium® Global Screening Array (GSA), for genetic risk screening of large global populations, and BC Platforms data management solutions, we will revolutionize the genomics field in Latin America, population risk assessment, and healthcare.
Codigo46 is located in Cuernavaca, Mexico, strategically located in the city where the best and brightest genomic scientists of Mexico are trained: the Genomic Sciences Center from UNAM. Our team consists of passionate, visionary, and knowledgeable people in bioinformatics, genetics, and international business. We believe in the ability of genomics to build a better future through the contribution and leadership in the generation of knowledge concerning diseases, wellness, populations, and ourselves. For more information, please visit www.codigo46.com.mx or email email@example.com.
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.
We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.